The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background: The PNPLA3 p.I148M impact on fat accumulation can be modulated by nutrients. Niacin (Vitamin B3) reduced triglycerides synthesis in in vitro and in vivo NAFLD models. Objectives: In this study, we aimed to investigate the niacin-I148M polymorphism crosstalk in NAFLD patients and examine niacin’s beneficial effect in reducing fat by exploiting hepatoma cells with different PNPLA3 genotype. Design: We enrolled 172 (Discovery cohort) and 358 (Validation cohort) patients with non-invasive and histological diagnosis of NAFLD, respectively. Dietary niacin was collected from food diary, while its serum levels were quantified by ELISA. Hepatic expression of genes related to NAD metabolism was evaluated by RNAseq in bariatric NAFLD patients (n = 183; Transcriptomic cohort). Hep3B (148I/I) and HepG2 (148M/M) cells were silenced (siHep3B) or overexpressed (HepG2 I148+) for PNPLA3, respectively. Results: In the Discovery cohort, dietary niacin was significantly reduced in patients with steatosis ≥ 2 and in I148M carriers. Serum niacin was lower in subjects carrying the G at risk allele and negatively correlated with obesity. The latter result was confirmed in the Validation cohort. At multivariate analysis, the I148M polymorphism was independently associated with serum niacin, supporting that it may be directly involved in the modulation of its availability. siHep3B cells showed an impaired NAD biosynthesis comparable to HepG2 cells which led to lower niacin efficacy in clearing fat, supporting a required functional protein to guarantee its effectiveness. Conversely, the restoration of PNPLA3 Wt protein in HepG2 I148+ cells recovered the NAD pathway and improved niacin efficacy. Finally, niacin inhibited de novo lipogenesis through the ERK1/2/AMPK/SIRT1 pathway, with the consequent SREBP1-driven PNPLA3 reduction only in Hep3B and HepG2 I148M+ cells. Conclusions: We demonstrated a niacin-PNPLA3 I148M interaction in NAFLD patients which possibly pave the way to vitamin B3 supplementation in those with a predisposing genetic background.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The advantages of the MASLD model in this cell line include reproducibility, preservation of key lipid metabolism pathways, high transfection efficiency, suitability for high-throughput screening (HTS), rapid lipid accumulation upon exposure to SFA, low cost, etc. [27,29,79].”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [79]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An important feature is the presence of a homozygous genotype for the PNPLA3 I148M (rs738409 C>G) variant, the strongest genetic predictor of MASLD susceptibility and progression.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [79]
The cited source says what the claim attributes to it.
In the citing paper
“This feature gives the model a number of specific phenotypic traits that are important for preclinical studies, since the presence of the mutant allele causes an increased tendency to steatosis in response to free fatty acid loading [79,80].”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, Y., Xu, S., Mihaylova, M. M., Zheng, B., Hou, X., Jiang, B., Park, O., Luo, Z., Lefai, E., Shyy, J. Y.-J., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.009 · Cited by 1,778
Non-invasive evaluation of liver fibrosis using transient elastography
Castera, L., Forns, X., & Alberti, A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.02.008 · Cited by 1,430 · cited 1×
“2 kPa defined a significant liver fibrosis (26, 27).”
BackgroundNampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme
Revollo, J. R., Körner, A., Mills, K. F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R. R., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.003 · Cited by 911 · cited 14×
“Consequently to the induction of SIRT1, Hep3B and HepG2I148 + cells showed a huge downregulation of genes involved in DNL after niacin administration, as acetyl-CoA carboxylase (ACC, p 0.05 vs Hep3B + PA, p 0.05 vs HepG2I148 + + PA, Figure 6E), fatty acid synthase (FASn, p 0.05 vs Hep3B + PA, p 0.05 vs HepG2I148 + + P…”
BackgroundInfluentialDetermination of reliability criteria for liver stiffness evaluation by transient elastography
Boursier, J., Zarski, J.-P., de Ledinghen, V., Rousselet, M.-C., Sturm, N., Lebail, B., Fouchard-Hubert, I., Gallois, Y., Oberti, F., Bertrais, S., et al. (2013) · Hepatology · doi:10.1002/hep.25993 · Cited by 662 · cited 1×
“2 kPa defined a significant liver fibrosis (26, 27).”
BackgroundValenti, L., Al‐Serri, A., Daly, A. K., Galmozzi, E., Rametta, R., Dongiovanni, P., Nobili, V., Mozzi, E., Roviaro, G., Vanni, E., et al. (2010) · Hepatology · doi:10.1002/hep.23622 · Cited by 651
Self-citationNicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review
CARLSON, L. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01528.x · Cited by 581
Rotman, Y., Koh, C., Zmuda, J. M., Kleiner, D. E., & Liang, J. T. (2010) · Hepatology · doi:10.1002/hep.23759 · Cited by 475
A feed-forward loop amplifies nutritional regulation of PNPLA3
Huang, Y., He, S., Li, J. Z., Seo, Y.-K., Osborne, T. F., Cohen, J. C., & Hobbs, H. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003585107 · Cited by 386 · cited 3×
“In particular, carbohydrates upregulate mutant PNPLA3 on lipid droplets surfaces, thus hindering their hydrolysis (34).”
BackgroundGariani, K., Menzies, K. J., Ryu, D., Wegner, C. J., Wang, X., Ropelle, E. R., Moullan, N., Zhang, H., Perino, A., Lemos, V., et al. (2016) · Hepatology · doi:10.1002/hep.28245 · Cited by 368 · cited 13×
“Consequently to the induction of SIRT1, Hep3B and HepG2I148 + cells showed a huge downregulation of genes involved in DNL after niacin administration, as acetyl-CoA carboxylase (ACC, p 0.05 vs Hep3B + PA, p 0.05 vs HepG2I148 + + PA, Figure 6E), fatty acid synthase (FASn, p 0.05 vs Hep3B + PA, p 0.05 vs HepG2I148 + + P…”
BackgroundInfluentialDongiovanni, P., Stender, S., Pietrelli, A., Mancina, R. M., Cespiati, A., Petta, S., Pelusi, S., Pingitore, P., Badiali, S., Maggioni, M., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12719 · Cited by 367 · cited 1×
“The environment is not the only predisposing factor to NAFLD which has a strong hereditable component and we previously demonstrated that hepatic fat is the main driver of the progression to end-stage liver damages in genetically predisposed individuals (1).”
BackgroundSelf-citationAdiponutrin Functions as a Nutritionally Regulated Lysophosphatidic Acid Acyltransferase
Kumari, M., Schoiswohl, G., Chitraju, C., Paar, M., Cornaciu, I., Rangrez, A. Y., Wongsiriroj, N., Nagy, H. M., Ivanova, P. T., Scott, S. A., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.008 · Cited by 316 · cited 2×
“demonstrated that the I148M polymorphism increases the hepatic lipogenic activity and TG synthesis (7).”
BackgroundBasuRay, S., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2017) · Hepatology · doi:10.1002/hep.29273 · Cited by 302 · cited 1×
“Moreover, it has been demonstrated that I148M variant disrupts ubiquitylation and proteasomal degradation of PNPLA3 thus resulting in the accumulation of mutated protein on lipid droplets and impaired lipids mobilization (12).”
BackgroundCharacterization of the human patatin-like phospholipase family
Wilson, P. A., Gardner, S. D., Lambie, N. M., Commans, S. A., & Crowther, D. J. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600185-jlr200 · Cited by 297 · cited 1×
“However, the longer side chain of methionine blocks the access of fatty acids to the catalytic site, thus hampering PNPLA3 hydrolytic activity (10).”
BackgroundAccumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis
BasuRay, S., Wang, Y., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901974116 · Cited by 284 · cited 1×
“The 148M substitution leads to a reduced fatty acid hydrolysis yielding an impaired mobilization of triglycerides (TG) which accumulate in the liver (8, 9).”
BackgroundChronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis
Li, J. Z., Huang, Y., Karaman, R., Ivanova, P. T., Brown, H. A., Roddy, T., Castro-Perez, J., Cohen, J. C., & Hobbs, H. H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65179 · Cited by 283 · cited 1×
“Consistently, in a murine model, the overexpression of the mutated PNPLA3 (I148M) in the liver increased fatty acids and TG formation, impaired TAG hydrolysis and weakened the remodeling of TAG long-chain polyunsaturated fatty acids (PUFAs) (11).”
BackgroundNiacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells
Ganji, S. H., Tavintharan, S., Zhu, D., Xing, Y., Kamanna, V. S., & Kashyap, M. L. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300403-jlr200 · Cited by 227
Santoro, N., Kursawe, R., D'Adamo, E., Dykas, D. J., Zhang, C. K., Bale, A. E., Calí, A. M., Narayan, D., Shaw, M. M., Pierpont, B., et al. (2010) · Hepatology · doi:10.1002/hep.23832 · Cited by 218
Davis, J. N., Lê, K.-A., Walker, R. W., Vikman, S., Spruijt-Metz, D., Weigensberg, M. J., Allayee, H., & Goran, M. I. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.30185 · Cited by 204 · cited 1×
“A nutrigenetic analysis revealed that the hepatic fat fraction in GG carriers is strongly influenced by carbohydrates and dietary sugar whose consumption may induce sterol-regulatory element binding protein-1C (SREBP1c) and, in turn, the expression of PNPLA3 mutated protein thus exacerbating fat deposition (16).”
BackgroundGanji, S. H., Kashyap, M. L., & Kamanna, V. S. (2015) · Metabolism · doi:10.1016/j.metabol.2015.05.002 · Cited by 142
Nutrition and Genetics in NAFLD: The Perfect Binomium
Meroni, M., Longo, M., Rustichelli, A., & Dongiovanni, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082986 · Cited by 139
Self-citationAge and sex of surgeons and mortality of older surgical patients: observational study
Tsugawa, Y., Jena, A. B., Orav, E. J., Blumenthal, D. M., Tsai, T. C., Mehtsun, W. T., & Jha, A. K. (2018) · BMJ · doi:10.1136/bmj.k1343 · Cited by 125
Mondul, A. M., Mancina, R. M., Merlo, A., Dongiovanni, P., Rametta, R., Montalcini, T., Valenti, L. V. C., Albanes, D., & Romeo, S. (2015) · Journal of Nutrition · doi:10.3945/jn.115.210633 · Cited by 119 · cited 1×
“It has been established that PNPLA3 may be modulated by nutrients thus affecting the response to dietary interventions (34, 35).”
BackgroundSelf-citationLongo, M., Meroni, M., Paolini, E., Erconi, V., Carli, F., Fortunato, F., Ronchi, D., Piciotti, R., Sabatini, S., Macchi, C., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.11.007 · Cited by 112
Self-citationSantoro, N., Savoye, M., Kim, G., Marotto, K., Shaw, M. M., Pierpont, B., & Caprio, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037827 · Cited by 108 · cited 1×
“In addition, hepatic fat accumulation can be modulated by the interaction between PNPLA3 I148M variant and dietary omega 6/omega 3 PUFAs and diet supplemented with n-3 respect to n-6 PUFA could provide a targeted therapy in NAFLD subjects who are homozygous for the PNPLA3 G allele (17).”
BackgroundBaselli, G. A., Dongiovanni, P., Rametta, R., Meroni, M., Pelusi, S., Maggioni, M., Badiali, S., Pingitore, P., Maurotti, S., Montalcini, T., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319226 · Cited by 106 · cited 1×
“RNA-seq was performed in a subset of 183 severely obese patients (31 without and 152 with NAFLD) in whom a percutaneous liver biopsy was performed during bariatric surgery at Fondazione IRCCS Cà Granda, Ospedale Policlinico, Milan, Italy (31).”
MethodSelf-citationMboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes
Meroni, M., Dongiovanni, P., Longo, M., Carli, F., Baselli, G., Rametta, R., Pelusi, S., Badiali, S., Maggioni, M., Gaggini, M., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102658 · Cited by 90
Self-citationLi, C., Li, L., Lian, J., Watts, R., Nelson, R., Goodwin, B., & Lehner, R. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304584 · Cited by 85
Hu, M., Chu, W. C. W., Yamashita, S., Yeung, D. K. W., Shi, L., Wang, D., Masuda, D., Yang, Y., & Tomlinson, B. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p023614 · Cited by 81 · cited 16×
“Consequently to the induction of SIRT1, Hep3B and HepG2I148 + cells showed a huge downregulation of genes involved in DNL after niacin administration, as acetyl-CoA carboxylase (ACC, p 0.05 vs Hep3B + PA, p 0.05 vs HepG2I148 + + PA, Figure 6E), fatty acid synthase (FASn, p 0.05 vs Hep3B + PA, p 0.05 vs HepG2I148 + + P…”
BackgroundInfluentialGanji, S. H., Kukes, G. D., Lambrecht, N., Kashyap, M. L., & Kamanna, V. S. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00181.2013 · Cited by 79 · cited 3×
“It has been previously demonstrated that niacin improves hepatic steatosis by downregulating DGAT2 and reducing TG synthesis which, in turn, lead to a decreased oxidative stress (19, 20).”
BackgroundNiacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?
Kashyap, M. L., Ganji, S., Nakra, N. K., & Kamanna, V. S. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.10.006 · Cited by 54 · cited 2×
“Furthermore, it has been demonstrated that niacin reverses oxidative stress and inflammation, in cells and animal models, possibly due to its effect in clearing lipids (38).”
Background(2016) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2016.00009 · Cited by 50
PNPLA3 Genotype and Risk of Liver and All‐Cause Mortality
Stender, S., & Loomba, R. (2020) · Hepatology · doi:10.1002/hep.31113 · Cited by 43 · cited 1×
“Moreover, the homozygosity for PNPLA3 risk allele has been associated with more than 2-fold greater risk to develop NASH and cirrhosis, with up to a 12-fold increased risk for HCC and with an 18-fold increase in liverrelated mortality (5, 6), thus suggesting a dose-dependent allele risk.”
BackgroundYe, L., Cao, Z., Lai, X., Shi, Y., & Zhou, N. (2020) · The Journal of Nutrition · doi:10.1093/jn/nxz303 · Cited by 39 · cited 15×
“Consequently to the induction of SIRT1, Hep3B and HepG2I148 + cells showed a huge downregulation of genes involved in DNL after niacin administration, as acetyl-CoA carboxylase (ACC, p 0.05 vs Hep3B + PA, p 0.05 vs HepG2I148 + + PA, Figure 6E), fatty acid synthase (FASn, p 0.05 vs Hep3B + PA, p 0.05 vs HepG2I148 + + P…”
BackgroundInfluentialMutant PNPLA3 I148M protein as pharmacological target for liver disease
Valenti, L., & Dongiovanni, P. (2017) · Hepatology · doi:10.1002/hep.29298 · Cited by 33 · cited 1×
“Finally, it has been shown that carbohydrates may induce the accumulation of mutant PNPLA3 on LD surface thus worsening hepatic fat content (13).”
BackgroundSelf-citationDietary Niacin Intake Predicts the Decrease of Liver Fat Content During a Lifestyle Intervention
Linder, K., Willmann, C., Kantartzis, K., Machann, J., Schick, F., Graf, M., Kümmerle, S., Häring, H., Fritsche, A., Stefan, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-38002-7 · Cited by 32 · cited 2×
“who observed a higher niacin-dependent reduction of hepatic steatosis in NAFLD patients who lost weight during a period of diet counselling and physical activity (25).”
BackgroundGómez, E. V., Pirola, C. J., Sookoian, S. C., Wilson, L., Liang, T., & Chalasani, N. (2022) · Hepatology · doi:10.1002/hep.32491 · Cited by 31
Nicotinamide and NAFLD: Is There Nothing New Under the Sun?
Guarino, M., & Dufour, J.-F. (2019) · Metabolites · doi:10.3390/metabo9090180 · Cited by 25
Blond, E., Rieusset, J., Alligier, M., Lambert-Porcheron, S., Bendridi, N., Gabert, L., Chétiveaux, M., Debard, C., Chauvin, M., Normand, S., et al. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1372600 · Cited by 22
MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients
Meroni, M., Longo, M., Paolini, E., Lombardi, R., Piciotti, R., Francione, P., Badiali, S., Maggioni, M., Fracanzani, A. L., & Dongiovanni, P. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13396 · Cited by 16
Self-citationXu, X. L., Deng, X., Chen, Y., Xu, W., Xu, F. L., & Liang, H. (2022) · Genes and Environment · doi:10.1186/s41021-022-00246-1 · Cited by 10 · cited 2×
“SIRT1, whose activity is dependent of NAD+ availability, is involved in the transcriptional regulation of SREBP-1c and in the epigenetic regulation of PNPLA3 gene by nutritional factors (33).”
Background
Cited by
SIRT1/SREBPs-mediated regulation of lipid metabolism
Shen, S., Shen, M., Kuang, L., Yang, K., Wu, S., Liu, X., Wang, Y., & Wang, Y. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107037 · Cited by 115
Samy, A. M., Kandeil, M. A., Sabry, D., Abdel-Ghany, A. A., & Mahmoud, M. O. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30387 · Cited by 60
PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease
Speliotes, E. K., & Schneider, C. V. (2024) · Liver International · doi:10.1111/liv.16106 · Cited by 33
Mechanisms coupling lipid droplets to MASLD pathophysiology
Reid, M. V., Fredrickson, G., & Mashek, D. G. (2024) · Hepatology · doi:10.1097/hep.0000000000001141 · Cited by 29
Weiskirchen, R., & Lonardo, A. (2024) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2024.70 · Cited by 23
Metadata
- Authors
- Paolini, E., Longo, M., Meroni, M., Tria, G., Cespiati, A., Lombardi, R., Badiali, S., Maggioni, M., Fracanzani, A. L., & Dongiovanni, P.
- Affiliations
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Corresponding author
- Dongiovanni, Paola
- ORCID
- Venue
- Frontiers in Nutrition
- Publisher
- Frontiers Media SA
- Published
- 2023-03-02
- Volume
- 10
- Pages
- 1101341-1101341
- ISSN
- 2296-861X (ISSN-L)
- PMC
- PMC10018489
- OpenAlex
- W4322769950
- Cited by
- 11
- References
- 40
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 2
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Nutrition (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministero della Salute
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- PNPLA3, I148M polymorphism, nicotinic acid, non-alcoholic fatty liver disease, genetic screening, NAD+ metabolism, hepatic steatosis, de novo lipogenesis, SREBP1, dietary niacin, obesity, hepatocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.